Evaluation of the Effects of Peiminine on Disease Activity Indices and Inflammatory Markers in an Experimental Model of Autoimmune Hepatitis
Abstract
Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease that can progress to cirrhosis and liver failure if untreated. Current therapies, mainly corticosteroids, are effective but limited by adverse effects and incomplete responses, prompting the search for safer alternatives. Peiminine, an alkaloid derived from Fritillaria species, has demonstrated anti-inflammatory and antioxidant properties in several disease models. This study evaluated its efficacy in a concanavalin A (ConA)–induced mouse model of AIH.
Male C57BL/6 mice were divided into six groups, including ConA-injured animals, and treatment groups receiving peiminine (3 mg/kg, i.p.), prednisolone (10 mg/kg, i.p.), or their combination.
ConA injection caused sharp increases in ALT (↑ 5.4-fold), AST (↑ 4.8-fold), and ALP (↑ 3.9-fold), alongside marked elevations in MPO activity, nitric oxide, and pro-inflammatory cytokines (TNF-α, IL-6, IFN-γ). Peiminine significantly reversed these alterations—reducing ALT, AST, and ALP by 65% to 75% and restoring IL-4, TGF-β, and SOD activity toward normal values. Pre-treatment provided stronger protection than post-treatment, and outcomes were comparable to those of prednisolone, with combination therapy yielding the greatest improvement across all indices.
These findings indicate that peiminine mitigates immune-mediated hepatic injury by modulating cytokines, reducing oxidative stress, and maintaining liver integrity. Peiminine may represent a promising preventive or adjunct therapy for AIH, warranting further mechanistic and long-term investigations.
2. Van Gerven NM, Verwer BJ, Witte BI, de Vries RA, de Boer YS, Mulder CJ, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014;49(10):1245–54.
3. Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. Scand J Gastroenterol. 2014;49(2):217–24.
4. Pape, S., Schramm, C., & Gevers, T. J. (2019). Clinical management of autoimmune hepatitis. United European gastroenterology journal, 7(9), 1156-1163.
5. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004.
6. Gong Q, Li Y, Ma H, Zhang Z, Wang S, Zhao H, et al. Peiminine protects against lipopolysaccharide-induced mastitis by inhibiting the AKT/NF-κB, ERK1/2 and p38 signaling pathways. Int J Mol Sci. 2018;19(9):2637.
7. Chao X, Wang G, Tang Y, Li P, Zhang H, Sun L, et al. The effects and mechanism of Peiminine-induced apoptosis in human hepatocellular carcinoma HepG2 cells. PLoS One. 2019;14(1):e0201864.
8. Zheng Z, Xu L, Zhang S, Li Y, Wang J, Chen X, et al. Peiminine inhibits colorectal cancer cell proliferation by inducing apoptosis and autophagy and modulating key metabolic pathways. Oncotarget. 2017;8(29):47619–31.
9. Luo Z, Zheng B, Jiang B, Xue X, Xue E, Zhou Y. Peiminine inhibits the IL-1β induced inflammatory response in mouse articular chondrocytes and ameliorates murine osteoarthritis. Food Funct. 2019;10(4):2198-208.
10. Sass G, Koerber K, Bang R, et al. Inducible nitric oxide synthase is critical for ConAinduced liver injury; iNOS deficiency or inhibition protects mice. J Clin Invest. 2001;107(4):439–447
11. Nabekura T, et al. Concanavalin-A-Induced Acute Liver Injury in Mice. Curr Protoc. 2024; 4(8): e1117. doi: 10.1002/cpz1.1117.
12. Cha SJ, Kim SS, Shin JH, Seo SR. Peiminine exerts anti-acne effects by regulating NF-κB in C. acnes-induced inflammation. Antioxidants (Basel). 2024;13(1):131.
13. Chen G, Huang B, Fu S, Li B. Peiminine protects dopaminergic neurons by inhibiting ERK1/2 and NF-κB. Int J Mol Sci. 2018;19(3):821.
14. Mizuhara H, Uno M, Seki N, et al. Critical role of IFN-γ in T-cell activation–associated hepatitis; IL-6 modulates disease manifestations. Hepatology. 1996;23(6):1608–1615.
15. Wang HX, Liu M, Weng SY, et al. Immune mechanisms of the ConA model of autoimmune hepatitis (review). World J Gastroenterol. 2012;18(2):119–125.
16. Liu Y, Wang L, Li Y. ConA-induced autoimmune hepatitis in mice: mechanisms and outlook (review). Biology (Basel). 2022;11(2):229
17. Huang TH, Chen CC, Liu PH, et al. Resveratrol pretreatment attenuates ConA-induced hepatitis via inflammatory and oxidative pathways. Sci Rep. 2017;7:41821.
18. Fei M, Xie Q, Zou Y, et al. α-Lipoic acid protects against ConA hepatitis by reducing ROS and modulating cytokines. Int Immunopharmacol. 2016;35:53–60.
19. Kwon HJ, Won YS, Park O, et al. Opposing effects of prednisolone in T/NKT-cell vs hepatotoxin hepatitis; prednisolone attenuates ConA hepatitis and cytokinemia. Hepatology. 2014;59(1):109–121.
20. Tiegs G, Hentschel J, Wendel A. A T-cell-dependent experimental liver injury in mice inducible by ConA; dexamethasone is protective. J Clin Invest. 1992;90(1):196–203.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Autoimmune hepatitis Combination therapy Immunomodulation Oxidative stress Peiminine | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
